Authors

Latest:

Chip Petricoin on the Discovery of New Biomarkers

Emanuel F. "Chip" Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.

Emanuela Palmerini, MD

Latest:

Dr. Palmerini on Long-term Efficacy of Denosumab in Giant Cell Tumor of Bone

Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Rizzoli Orthopaedic Institute, discusses the long-term efficacy of denosumab (Xgeva) in patients with giant cell tumor of bone.

Emese Zsiros, MD, PhD

Latest:

Dr. Zsiros Discusses Pembrolizumab Triplet in Recurrent Ovarian Cancer

Emese Zsiros, MD, PhD, discusses the results of her recent phase II trial that set out to evaluate the use of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Emiel J. Rutgers, MD

Latest:

Dr. Rutgers Compares ART or ALND in Breast Cancer

Emiel J. Rutgers, MD, surgical oncologist, Netherlands Cancer Institute, Amsterdam, discusses a study analyzing radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients.

Emil Israel Cohen, MD

Latest:

Dr. Cohen on Eligibility for Ablation Therapy in Liver Cancer

Emil Israel Cohen, MD, an assistant professor at Medstar Georgetown University Hospital, discusses the criteria for ablation therapy in patients with liver cancer.

Emily A. Barber, BS

Latest:

Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer

This review will focus on current therapies used in the first-line setting for advanced EGFR mutation positive non–small cell lung cancer (NSCLC) followed by emerging data that may lead to a transition in the choice for initial therapy in these patients.

Emily Brill

Latest:

From "Least Engaged" to "Most Happy": 4 Types of OCM Participant

The goal of the Oncology Care Model is to incentivize high-quality, coordinated care with an episode-based payment model that emphasizes patient access and navigation.

Emily Chan, MD, PhD

Latest:

Dr. Chan Discusses the VEGF-Trap Agent Aflibercept

Dr. Emily Chan, from Vanderbilt-Ingram Cancer Center, Discusses the VEGF-Trap Agent Aflibercept

Emily Ko, MD

Latest:

Dr. Ko on Surgery as an Effective Option for Patients With Endometrial Cancer

Emily Ko, MD, assistant professor of Obstetrics and Gynecology, University of Pennsylvania Health System, discusses why surgery is an effective option for patients with endometrial cancer.

Emma Barber, MD

Latest:

Dr Barber on the Significance of the KEYNOTE-775 Trial for the Second-line Treatment of Endometrial Cancer

Emma L. Barber, MD, discusses how key data from the phase 3 KEYNOTE-775 study improved the identification of patient populations within endometrial cancer that benefit from second-line immunotherapy.

Emma Hitt, PhD

Latest:

Novel Agents Revolutionize Melanoma Treatment

Until recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with dacarbazine (DTIC) and immunotherapy with high-dose interleukin-2 (HD IL-2) or interferon-Î± (IFN-Î±).

Emma S. C. Carr, BSc, MSc, PhD

Latest:

Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced Patients

A mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.

Emmanuel S. Antonarakis, MBBCh

Latest:

Dr. Antonarakis on Trial Examining Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

Emmanuel S. Antonarakis, MBBCh, discusses the design of a randomized phase II study of sipuleucel-T with or without radium-223 dichloride in men with asymptomatic bone-metastatic castrate-resistant prostate cancer.

Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine

Emmanuel S. Antonarakis, MD

Latest:

Drs Antonarakis and Jha on Extending Clinical Trials to the Community Setting

Emmanuel Antonarakis, MD, and Gautam Jha, MD, on collaboration efforts extending the reach of clinical trials beyond university hospitals.

Enrico Tiacci, MD

Latest:

Dr. Tiacci on Vemurafenib and Rituximab Combo in Hairy Cell Leukemia

Enrico Tiacci, MD, discusses updated data of a phase II trial investigating the combination of vemurafenib and rituximab for patients with relapsed/refractory hairy cell leukemia.

Enrique Grande, MD

Latest:

Dr. Grande on the Rationale of the IMvigor130 Trial in Urothelial Cancer

Enrique Grande, MD, discusses the rationale of the IMvigor130 trial in urothelial cancer.

Enrique Soto Perez de Celis, MD, MSc

Latest:

Dr. Soto Perez de Celis on COVID-19 Risk Reduction

Enrique Soto Pérez de Celis, MD, MSc, a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City, Mexico, discusses ways to reduce the risk of contracting the novel coronavirus 2019 (COVID-19).

Enriqueta Felip, MD

Latest:

Dr. Felip on Immunotherapy Alone or in Combination in Lung Cancer

Enriqueta Felip, MD, discusses immunotherapy alone versus immunotherapy plus chemotherapy in patients with lung cancer.

Enriqueta Felip, MD, PhD

Latest:

Dr. Felip Discusses Ceritinib's Response in ALK+ NSCLC

Enriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).